Gates Foundation Strategic Investment Fund Logo
Share this page:

Portfolio

Our investments accelerate growth and stimulate private sector innovation and investment, giving our partners additional tools to effect change and improve lives. We make investments that align with foundation issue areas from vaccine development to education in the United States.

More on the types of investments we make.

Here you can explore our current and past investments, filtered by issue area or investment type.

Achaogen Logo

Achaogen

Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation’s investment is supporting the development of Achaogen’s monoclonal antibody (“mAb”) discovery platform.

Press Release
Affinivax Logo

Affinivax

Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine.

News Story
amyris logo

Amyris

The foundation invested in Amyris to support the development of new, low-cost technologies for manufacturing compounds to make semi-synthetic artemisinin that can be used in anti-malaria treatments.

Anacor Logo

Anacor Pharmaceuticals

Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation partnered with the team to support development of preclinical drug candidates.

Press Release
Case Study
News Story
Arsanis Logo

Arsanis

Arsanis is focused on discovery and development of novel monoclonal antibodies (“mAbs”) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis which leads to approximately 345,000 annual deaths globally.

Press Release
News Story
AuroBindo Logo

Aurobindo Dolutegravir

Aurobindo Pharma, along with Mylan Laboratories, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price.

Press Release
Case Study
CureVac Logo

CureVac

The foundation invested in CureVac to accelerate vaccine technology development, getting life-saving and low-cost vaccines to people who need them most.

Press Release
News Story

Evolve BioSystems

Evolve BioSystems is an infant microbiome company dedicated to developing the next generation of products to establish, restore and maintain a healthy gut microbiome. The foundation is working with Evolve to further develop and apply its lead probiotic, Evivo, to Read More

Press Release
Genocea Logo

Genocea

Genocea harnesses the power of T cells to discover life-changing vaccines and immunotherapies. The foundation partnered with the team to identify antigens for future malaria vaccines as T cell response is critical during the liver-stage of disease.

Press Release
Case Study
immunocore logo

Immunocore

Immunocore develops innovative biological therapeutics that exploit the power of the body’s own immune system to find and kill diseased cells. The foundation partnered with the company to expand its focus into infectious disease.

Press Release